» Articles » PMID: 9621079

Novel Gag-Pol Frameshift Site in Human Immunodeficiency Virus Type 1 Variants Resistant to Protease Inhibitors

Overview
Journal J Virol
Date 1998 Jun 17
PMID 9621079
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Human immunodeficiency virus type 1 (HIV-1) variants resistant to protease inhibitors have been shown to contain a mutation in the p1/p6 Gag precursor cleavage site. At the messenger RNA level, this mutation generates a U UUU UUU sequence that is reminiscent of the U UUU UUA sequence required for ribosomal frameshifting and Gag-Pol synthesis. To test whether the p1/p6 cleavage site mutation was generating a novel frameshift site, HIV sequences were inserted in translation vectors containing a chloramphenicol acetyltransferase (CAT) reporter gene requiring -1 frameshifting for expression. All sequences containing the original HIV frameshift site supported the synthesis of CAT but expression was increased 3- to 11-fold in the presence of the mutant p1/p6 sequence. When the original frameshift site was abolished by mutation, expression remained unchanged when using constructs containing the mutant p1/p6 sequence, whereas it was decreased 2- to 4.5-fold when using wild-type p1/p6 constructs. Similarly, when introduced into HIV molecular clones, the p1/p6 mutant sequence supported Gag-Pol synthesis and protease activity in the absence of the original frameshift site, indicating that this sequence could also promote ribosomal frameshifting in virus-expressing cells.

Citing Articles

Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease.

Motyan J, Mahdi M, Hoffka G, Tozser J Int J Mol Sci. 2022; 23(7).

PMID: 35408866 PMC: 8998604. DOI: 10.3390/ijms23073507.


HIV-1 Mutant Assembly, Processing and Infectivity Expresses Pol Independent of Gag.

Yu F, Huang K, Wang C Viruses. 2020; 12(1).

PMID: 31906562 PMC: 7019881. DOI: 10.3390/v12010054.


Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication.

Maeda K, Das D, Kobayakawa T, Tamamura H, Takeuchi H Curr Top Med Chem. 2019; 19(18):1621-1649.

PMID: 31424371 PMC: 7132033. DOI: 10.2174/1568026619666190712204603.


Mechanisms and biomedical implications of -1 programmed ribosome frameshifting on viral and bacterial mRNAs.

Korniy N, Samatova E, Anokhina M, Peske F, Rodnina M FEBS Lett. 2019; 593(13):1468-1482.

PMID: 31222875 PMC: 6771820. DOI: 10.1002/1873-3468.13478.


Modulation of HIV-1 Gag/Gag-Pol frameshifting by tRNA abundance.

Korniy N, Goyal A, Hoffmann M, Samatova E, Peske F, Pohlmann S Nucleic Acids Res. 2019; 47(10):5210-5222.

PMID: 30968122 PMC: 6547452. DOI: 10.1093/nar/gkz202.


References
1.
Adachi A, Gendelman H, Koenig S, Folks T, Willey R, Rabson A . Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986; 59(2):284-91. PMC: 253077. DOI: 10.1128/JVI.59.2.284-291.1986. View

2.
Zhang Y, Imamichi H, Imamichi T, Lane H, Falloon J, Vasudevachari M . Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol. 1997; 71(9):6662-70. PMC: 191944. DOI: 10.1128/JVI.71.9.6662-6670.1997. View

3.
Veronese F, Rahman R, Copeland T, Oroszlan S, Gallo R, Sarngadharan M . Immunological and chemical analysis of P6, the carboxyl-terminal fragment of HIV P15. AIDS Res Hum Retroviruses. 1987; 3(3):253-64. DOI: 10.1089/aid.1987.3.253. View

4.
Higuchi R, Krummel B, Saiki R . A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res. 1988; 16(15):7351-67. PMC: 338413. DOI: 10.1093/nar/16.15.7351. View

5.
Seed B, Sheen J . A simple phase-extraction assay for chloramphenicol acyltransferase activity. Gene. 1988; 67(2):271-7. DOI: 10.1016/0378-1119(88)90403-9. View